Nuclear Medicine Communications最新文献

{"title":"Qualitative and quantitative analysis of reduced bed position acquisition time on FDG PET image quality.","authors":"Michael Ting, Garry McDermott, Amir Zarei, Chirag Patel, Fahmid U Chowdhury, Andreia Rodrigues, Andrew F Scarsbrook","doi":"10.1097/MNM.0000000000001957","DOIUrl":"10.1097/MNM.0000000000001957","url":null,"abstract":"<p><p>The study aim was to evaluate whether reducing bed position acquisition time would result in significant detriment to image quality. Secondary aims were to compare effect of time of flight (TOF) and Q.Clear reconstructions and patient BMI on image quality. Fluorodeoxyglucose PET-CT performed in 30 patients on a new scanner at our institution between March and May 2024 was retrospectively evaluated. Four PET reconstructions were performed: (a) 1 min 45 s TOF, (b) 2 min TOF, (c) 1 min 45 s Q.Clear, and (d) 2 min Q.Clear. For qualitative analysis, four maximum intensity projection images were evaluated side-by-side using a five-point visual score (1 = non-diagnostic, 5 = excellent). For quantitative analysis, liver signal-to-noise ratio (SNR) was calculated. A statistically significant reduction in visual score occurred when reducing bed position time from 2 min to 1 min 45 s (mean TOF scores 0.24 reduction, P = 0.0002; mean Q.Clear scores 0.04 reduction, P  = 0.02. There was also a statistically significant difference in liver SNR when reducing bed position time. Deterioration in image quality was minimised when bed position acquisition time was reduced if Q.Clear construction was utilized. This could facilitate increased scanning capacity without clinical detriment.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"362-366"},"PeriodicalIF":1.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11878577/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143009408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Network topology and metabolic alterations in early- and mid-stage Parkinson's disease: insights from fluorodeoxyglucose PET imaging.","authors":"Min Li, Jianpeng Liu, Rongbin Lv, Fangfei Liu, Guangbin Wang, Jiyuan Wang, Juan Cheng, Mingsheng Jia, Na Wang, Shuyong Liu","doi":"10.1097/MNM.0000000000001951","DOIUrl":"10.1097/MNM.0000000000001951","url":null,"abstract":"<p><strong>Objectives: </strong>Parkinson's disease (PD) is a neurodegenerative disorder with distinct metabolic alterations in the brain, which are detectable via 18 F-FDG PET. This study aims to delineate glucose metabolism patterns and network topology changes across early- and mid-stage PD patients.</p><p><strong>Methods: </strong>A total of 80 PD patients (Hoehn-Yahr stages 1-3) were retrospectively analyzed, including 40 early-stage and 40 mid-stage cases, along with 40 age-matched healthy controls. All participants underwent 18 F-FDG PET imaging. The brain metabolic activity was quantified, and network topology was assessed using graph theory metrics. Statistical comparisons between PD stages and control groups were performed to identify significant differences in metabolic patterns and network alterations.</p><p><strong>Results: </strong>Early-stage PD patients exhibited hypermetabolism in regions such as the pons and thalamus, with significant differences in metabolic activity compared with controls. Mid-stage PD patients showed more extensive hypermetabolism in the pons, right cerebellum, and putamen, alongside hypometabolism in the cuneus and calcarine regions. Hub node connectivity analysis revealed decreased connectivity in temporal and occipital lobes for both stages, while the limbic and frontal lobes showed enhanced connectivity. Compared with early-stage PD, mid-stage PD had reduced connectivity in the limbic system but increased in the frontal and occipital lobes.</p><p><strong>Conclusions: </strong>18 F-FDG PET imaging reveals progressive metabolic disruptions and network changes in PD, offering potential biomarkers for disease staging and therapeutic targeting, while also aiding in the understanding of disease progression and guiding therapeutic interventions.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"347-355"},"PeriodicalIF":1.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143009405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of EGFR mutation status and its subtypes in non-small cell lung cancer based on 18 F-FDG PET/CT radiological features.","authors":"Yishuo Fan, Yuang Liu, Xiaohui Ouyang, Jiagui Su, Xiaohong Zhou, Qichen Jia, Wenjing Chen, Wen Chen, Xiaofei Liu","doi":"10.1097/MNM.0000000000001948","DOIUrl":"10.1097/MNM.0000000000001948","url":null,"abstract":"<p><strong>Purpose: </strong>Prediction of epidermal growth factor receptor (EGFR) mutation status and subtypes in patients with non-small cell lung cancer (NSCLC) based on 18 F-fluorodeoxyglucose ( 18 F-FDG) PET/computed tomography (CT) radiomics features.</p><p><strong>Patients and methods: </strong>Retrospective analysis of 201 NSCLC patients with 18 F-FDG PET/CT and EGFR genetic testing was carried out. Radiomics features and clinical factors were used to construct a combined model for identifying EGFR mutation status. Mutation/wild-type models were trained in a training cohort ( n  = 129) and validated in an internal validation cohort ( n  = 41) vs an external validation cohort ( n  = 50). A second model predicting the 19/21 mutation locus was also built and evaluated in a subset of EGFR mutations (training cohort, n  = 55; validation cohort, n  = 14). The predictive performance and net clinical benefit of the models were assessed by analysis of the area under curve (AUC) of the subjects, nomogram, calibration curve and decision curve.</p><p><strong>Results: </strong>The AUC of the combined model distinguishing EGFR mutation status was 0.864 in the training cohort and 0.806 and 0.791 in the internal vs external test sets respectively, and the AUC of the 19/21 mutation site model was 0.971 and 0.867 in the training cohort and internal validation cohort respectively. The calibration curves of the individual models showed better model predictions (Brier score <0.25). Decision curve analysis showed that the models had clinical application.</p><p><strong>Conclusion: </strong>The combined model based on 18 F-FDG PET/CT radiomics features combined and clinical features can predict EGFR mutation status and subtypes in NSCLC patients, and guiding targeted therapy, and facilitate precision medicine development.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"326-336"},"PeriodicalIF":1.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143009406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A new therapeutic paradigm: radioiodine combined with lenvatinib for radioiodine-avid metastatic well-differentiated thyroid cancer.","authors":"Siddharth Sharma, Aftab Hasan Nazar, Prabhakar Mishra, Manish Ora, Amitabh Arya, Sukanta Barai, Prasanta Kumar Pradhan, Sanjay Gambhir","doi":"10.1097/MNM.0000000000001980","DOIUrl":"https://doi.org/10.1097/MNM.0000000000001980","url":null,"abstract":"<p><strong>Purpose: </strong>Management of metastatic well-differentiated thyroid cancer (WDTC) remains challenging, with significant morbidity and mortality. Multidisciplinary treatment, along with high-dose radioiodine therapy (HDRI), remains a mainstay. Morbidity and mortality benefits are noted, with seldom complete response. The foremost concerns are HDRI side effects, radioiodine refractoriness, macronodular lung, and bone metastasis. Lenvatinib is a standard of care in radioiodine-refractory disease. However, it remains unexplored in radioiodine-avid metastatic WDTC. This study investigates the effect of lenvatinib with HDRI in improving disease control and progression in radioiodine-avid metastatic WDTC.</p><p><strong>Material and methods: </strong>Fifteen patients with metastatic WDTC were enrolled with or without prior HDRI. The disease burden was evaluated with imaging [whole-body radioiodine scan (WBRI), PET-computed tomography (CT), or CT] and serum thyroglobulin (Tg) measurement. After excluding contraindication, lenvatinib was given for 3 months, along with thyroxine suppression. Adverse effects were monitored. Thyroxin was withdrawn, and the patient underwent WBRI followed by HDRI. Treatment response was evaluated based on imaging [response evaluation criteria in solid tumors (RECIST), PET response criteria in solid tumors (PERCIST), and WBRI] and tumor marker (Tg) parameters.</p><p><strong>Results: </strong>The mean age was 52.0 ± 14.2 years. Lung and bone metastases were noted in (12, 80%) and 10 (66%) patients. Nine (60%) patients already had HDRI (242.5 ± 140.3 mCi). Lenvatinib was well-tolerated, with two-thirds of patients having grade I toxicities. During follow-up (14.79 ± 5.93 months), one patient died of pneumonia unrelated to WDTC. Tg level fell from 45 800.8 ± 69 283.9 [median: 7094.0, interquartile range (IQR): 988.3-114 397.0] to 10 672.5 ± 18 490.5 (median: 1796.0, IQR: 171.0-17 090.0) ng/ml. Tg fall was not associated (P > 0.05) with age, sex, histopathology, and previous HDRI. Partial response and stable disease were noted in 10 and four patients, respectively, based on imaging (PERSIST and RECIST criteria) and tumor marker levels. One patient had disease progression on Tg and imaging.</p><p><strong>Conclusion: </strong>HDRI, in combination with lenvatinib, demonstrated potential benefits in radioiodine-avid metastatic WDTC. The combination treatment was well-tolerated. There was an unprecedented fall in tumor marker level and partial response on imaging by a single cycle of the therapy. While a small sample size limited the study, preliminary data suggest that the synergistic effect may improve disease control. Further investigation with a larger cohort is warranted to confirm findings and explore potential response predictors.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring utilities of [ 64 Cu]Cu-DOTA-trastuzumab immunoPET in breast cancer: a systematic review and meta-analysis.","authors":"Ahmed Saad Abdlkadir, Sudqi Allouzi, Shahed Obeidat, Miriam Mikhail-Lette, Hongcheng Shi, Akram Al-Ibraheem","doi":"10.1097/MNM.0000000000001949","DOIUrl":"10.1097/MNM.0000000000001949","url":null,"abstract":"<p><p>[ 64 Cu]Cu-DOTA-trastuzumab represents a novel immunopositron emission tomography (immunoPET) agent with emerging diagnostic applications in human epidermal growth factor receptor-2 (HER2)-expressing breast cancer (BC). This systematic review and meta-analysis evaluates the current diagnostic utilities of [ 64 Cu]Cu-DOTA-trastuzumab PET/computed tomography (CT) and explores tumor uptake metrics in HER2-positive BC lesions. A systematic literature search of PubMed , Scopus , and Ovid databases was conducted using relevant keywords to identify eligible studies. Of the 123 articles reviewed, six met the inclusion criteria. Qualitative data analysis was applied to all included studies. Several promising utilities were identified, including [ 64 Cu]Cu-DOTA-trastuzumab's capacity to detect HER2-positive primary BC lesions, lymph nodes, and distant metastases. Additionally, [ 64 Cu]Cu-DOTA-trastuzumab PET/CT demonstrated potential in predicting therapy response in HER2-positive lesions. The overall lesion detectability was 91% [95% confidence interval (CI), 81-98%] for HER2-positive BC. HER2-positive BC lesions exhibited significantly higher maximum standardized uptake values compared to HER2-negative lesions, with a weighted mean difference of 2.14 (95% CI, 0.18-4.09; P  = 0.03). These findings underscore the need for further large-scale and prospective investigations of this promising radiotracer in the near future.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":"277-284"},"PeriodicalIF":1.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143009404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"PET imaging of atherosclerosis: artificial intelligence applications and recent advancements.","authors":"Shaheer Rizwan, Cyrus Ayubcha, Omar Al-Daoud, Mamdouh Al-Atout, Raisa Amiruddin, Thomas J Werner, Abass Alavi","doi":"10.1097/MNM.0000000000001973","DOIUrl":"https://doi.org/10.1097/MNM.0000000000001973","url":null,"abstract":"<p><p>PET imaging has become a valuable tool for assessing atherosclerosis by targeting key processes such as inflammation and microcalcification. Among available tracers, 18F-sodium fluoride has demonstrated superior performance compared to 18F-fluorodeoxyglucose, particularly in detecting coronary artery disease. However, the role of other tracers remains underexplored, requiring further validation. Emerging technologies such as artificial intelligence show potential in enhancing diagnostic speed and accuracy. Furthermore, the integration of the Alavi-Carlsen Calcification Score offers a novel approach to evaluating global disease burden, presenting a more clinically applicable method for predicting outcomes. Techniques such as total-body PET provide faster and more comprehensive imaging of the entire vascular system with reduced radiation exposure, representing a significant advancement in early detection and intervention. The combination of molecular imaging and advanced computational tools may revolutionize the management of atherosclerosis, facilitating earlier identification of at-risk individuals and improving long-term cardiovascular outcomes.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143719870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of 68Ga-FAPI PET/CT imaging in gynecological cancers: an integrative review.","authors":"Sharjeel Usmani, Khulood Al Riyami, Nisar Ahmed, Ikram A Burney","doi":"10.1097/MNM.0000000000001977","DOIUrl":"https://doi.org/10.1097/MNM.0000000000001977","url":null,"abstract":"<p><p>Clinical staging of gynecological cancers traditionally employs computed tomography (CT) scan or 18fluorine-deoxyglucose PET/CT (18F-FDG PET/CT), which have limited sensitivity, especially for early-stage ovarian cancer, borderline tumors, tumors with cystic/mucinous components, and those with low metabolic activity. Fibroblast activation protein inhibitor (FAPI) targets cancer-associated fibroblasts in tumor stroma independent of metabolic activity, providing favorable tumor-to-background contrast when used with PET imaging. We conducted an integrative review of FAPI PET/CT use in gynecological cancers for staging, treatment response assessment, and recurrence detection. Database searches yielded 205 documents, with 23 studies meeting inclusion criteria (12 original research articles, 7 case reports, 4 reviews). 68Ga-FAPI PET/CT image was reported to be superior to 18F-FDG PET/CT in differentiating high-grade from lower-grade ovarian cancer, detection of nodal, peritoneal, and pleural disease, as well as early relapses. 68Ga-FAPI PET/CT showed enhanced detection of lymph node metastasis in newly diagnosed cervical cancer. However, its utility in endometrial cancer is limited by physiological uptake in normal uterine tissue. 68Ga-FAPI PET/CT shows promising results for diagnosis and staging of ovarian and cervical cancers. Further research is warranted as this modality has potential to modify treatment approaches by improving detection capabilities beyond conventional imaging techniques, particularly for tumors with challenging characteristics that limit current diagnostic methods.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143701108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting the spread through air spaces in lung adenocarcinoma from preoperative 18F-FDG PET/CT radiomics.","authors":"Xiaohui Chen, Hongliang Qi, Yijin Zou, Ye Chen, Hanwei Li, Debin Hu, Li Jiang, Meng Wang, Li Chen, Hongwen Chen, Hubing Wu","doi":"10.1097/MNM.0000000000001975","DOIUrl":"https://doi.org/10.1097/MNM.0000000000001975","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to develop an effective radiomics-clinical model to preoperatively discriminate the spread through air spaces (STAS) in lung adenocarcinoma (ADC).</p><p><strong>Methods: </strong>Data from 192 ADC patients were enrolled, with 2/3 (n = 128) allocated as the training cohort and the remaining 1/3 (n = 64) designated as the validation cohort. A total of 2212 radiomics features were extracted from PET/computed tomography (PET/CT) images. The least absolute shrinkage and selection operator regression method was applied to select features. Logistic regression was used to construct radiomics and clinical models. Finally, a radiomics-clinical model that combined clinical with radiomics features was developed. The models were evaluated by receiver operating characteristic (ROC) curve and decision curve analysis.</p><p><strong>Results: </strong>The area under the ROC curve (AUC) of the radiomics-clinical model was 0.924 (95% confidence interval, 0.878-0.969) in the training cohort and 0.919 (0.833-1.000) in the validation cohort. The AUC of the radiomics model was 0.885 (0.825-0.945) in the training cohort and 0.877 (0.766-0.988) in the validation cohort. The AUC of the clinical model was 0.883 (0.814-0.951) in the training cohort and 0.896 (0.7706-1.000) in the validation cohort. The decision curve analysis indicated its clinical usefulness.</p><p><strong>Conclusion: </strong>The PET/CT-based radiomics-clinical model achieved satisfactory performance in discriminating the STAS in ADC preoperatively.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143649522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic significance of total metabolic tumor volume on baseline 18F-FDG PET/CT in patients with lung adenocarcinoma: further stratification of the ninth edition of TNM staging subgroups.","authors":"Ruiqiu Zhang, Xiaohui Zhang, Qiaoling Gao, Han Zhang, Lianyu Gu, Xiuyu Guo, Jingfeng Zhang, Jianjun Zheng, Maoqing Jiang","doi":"10.1097/MNM.0000000000001976","DOIUrl":"https://doi.org/10.1097/MNM.0000000000001976","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to investigate the prognostic value of baseline total metabolic tumor volume (TMTV) on 18F-fluorodeoxyglucose positron emission tomography/computed tomography and its potential for further stratification within the ninth tumor-node-metastasis (TNM) staging system in patients with lung adenocarcinoma (LUAD).</p><p><strong>Methods: </strong>A cohort of 384 patients with LUAD who had undergone pretreatment PET/CT were included in this retrospective study. The optimal cutoff value for TMTV was determined through analysis of time-dependent receiver operating characteristic curves. The analysis of overall survival (OS) was conducted utilizing Kaplan-Meier curves. Predictive capacity was evaluated using the C statistic.</p><p><strong>Results: </strong>The optimal cutoff value for TMTV was 40.13 ml. The survival rates of patients varied significantly across stages I (n = 164), II (n = 37), III (n = 46), and IV (n = 137); however, there was no statistically significant difference between stages II and III (P = 0.440). In stages II-IV, the 2-year OS rates for patients with TMTV less than 40.13 ml were significantly higher at 81.7 and 86.7%, respectively, compared with patients with TMTV greater than equal to 40.13 ml who had rates of only 56.5 and 42.5%. No patients with stage I presented TMTV greater than or equal to 40.13 ml, and the 2-year OS rate was 98.3%. The C index did not reveal a significant difference between TNM and TMTV in their predictive ability for OS (0.83 vs. 0.85, P = 0.159).</p><p><strong>Conclusion: </strong>The TNM staging system demonstrates robust prognostic utility in patients with LUAD, while the incorporation of baseline TMTV may offer additional risk stratification within distinct TNM stages.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical combined PET/CT radiomics model prediction of benefit from platinum-based chemotherapy and chemoradiotherapy in patients with small cell lung cancer.","authors":"Mengye Peng, Xinyue Yang, Yanmei Wang, Liangqin Zhou, Fan Ge, Shijia Liu, Wei Liu, Liang Cheng, Kezheng Wang","doi":"10.1097/MNM.0000000000001971","DOIUrl":"https://doi.org/10.1097/MNM.0000000000001971","url":null,"abstract":"<p><strong>Objective: </strong>To develop and validate a clinical combined radiomics model for predicting the treatment response and long-term survival prognosis of small cell lung cancer (SCLC) patients receiving platinum-based chemotherapy, as well as survival outcomes following chemoradiotherapy.</p><p><strong>Methods: </strong>A total of 98 SCLC patients treated with platinum-based first-line chemotherapy were included in this study. Five prediction models for assessing the short-term efficacy of platinum-based first-line chemotherapy were developed using a logistic regression algorithm. The performance of the models was assessed by calculating the area under the curve of the receiver operating characteristic curves. For predicting progression-free survival (PFS) and overall survival in the platinum-based chemotherapy group and the chemoradiotherapy group, the optimal cutoff value was determined using X-tile software. Kaplan-Meier survival curves were plotted, and the log-rank test was used to compare survival outcomes.</p><p><strong>Results: </strong>Among the five models for predicting short-term efficacy, the clinical combined positron emission tomography/computed tomography (PET/CT) radiomics model performed the best, achieving areas under the curve of 0.832 and 0.833 for the training and test sets, respectively. The Kaplan-Meier survival analysis indicated that both the high-scoring Combine group and high-scoring PET/CT group were significantly associated with worse PFS and worse overall survival in the platinum-only chemotherapy group. Additionally, the high-scoring CT group was significantly associated with worse PFS in the chemoradiotherapy group.</p><p><strong>Conclusion: </strong>The clinical combined PET/CT radiomics model can noninvasively and accurately predict the response to platinum-based treatments in SCLC as well as long-term survival prognosis, which can contribute to personalized treatment strategies and guide precision therapy for SCLC patients.</p>","PeriodicalId":19708,"journal":{"name":"Nuclear Medicine Communications","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143625856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}